Harinath N. More
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Harinath N. More has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Firoj Allauddin Tamboli
Department of Pharmacognosy, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari, Kolhapur - 416013 Maharashtra, India
3 shared publications - Prafulla Balkrishna Choudhari
Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur, India
3 shared publications - Ashok Ananda Hajare
Bharati Vidyapeeth College of Pharmacy, Palus, Maharashtra, India 416310
2 shared publications - Laxman D. Khatal
Bharati Vidyapeeth College of Pharmacy, Kolhapur, Near Chitranagri, Kolhapur - 416013, Maharashtra, India
2 shared publications - Rakesh Pandit Dhavale
Department of Pharmaceutics, Bharati Vidyapeeth College of Pharmacy, Kolhapur, India
2 shared publications - Sanket Rathod
Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur 416013, Maharashtra, India
2 shared publications
Latest Publications
- 16 December 2024
- Published by Springer Nature in Chemistry Africa
- Vol. 8 (1) , 115-135
In Vivo Screening and In Silico Structure-Based Characterization of Synthesized Oxadiazole Derivatives with Potential Anticonvulsant Activity
- 16 December 2024
- Published by Springer Nature in Chemistry Africa
- Vol. 8 (1) , 115-135
In Vivo Screening and In Silico Structure-Based Characterization of Synthesized Oxadiazole Derivatives with Potential Anticonvulsant Activity
- Open Access
- 4 April 2024
- Published by Wiley in Journal of Chemistry
- Vol. 2024, 1-19
Novel Phytosomal Formulation of Emblica officinalis Extracts with Its In Vivo Nootropic Potential in Rats: Optimization and Development by Box-Behnken Design
Purpose. The present study aimed to improve the aqueous solubility, permeability, bioavailability, and nootropic potential of standardized Emblica officinalis extract (EOE) by developing a novel phytosomal formulation. Method. Emblica officinalis extract-loaded phytosomes (EOPs) were prepared using solvent evaporation. The EOP was prepared at different molar ratios of extract and phospholipid. Herein, the effects of phospholipid extract ratio (A), temperature (B), and reaction time (C) were systematically investigated on entrapment efficiency using Box-Behnken design. In vitro and in vivo characterizations of the optimized formulation were performed. Results. Optimized EOP formulation (89.90 ± 0.24 μg/ml) exhibited improved aqueous solubility than plain EOE (11.85 ± 0.25 μg/ml). The optimized formulation’s particle size and Zeta potential were 198.4 ± 0.20 nm and −39.0 ± 0.40 mv. DSC and XRD studies confirmed the partial amorphization of EOE in phytosomes. Optimized formulation exhibited 69.82 ± 0.17% of EOE release at 12 h and followed zero-order release kinetics. Moreover, the phytosomal formulation of EOE exhibited its rationality with an improvement of bioavailability by 2.7 folds compared with pure EOE. Compared to EOE, EOP showed significantly ( lower escape and transfer latencies on both days in MWMT and EPMT, indicating more effective memory-enhancing activity. Furthermore, EOP-treated rats exhibited improved acetylcholine (Ach) levels than EOE. Brain tissue concentrations measured following EOP oral administration (1.06 ± 0.04 μg/ml) were substantially greater ( ) than those following EOE (0.32 ± 0.07 μg/ml). The brain dopamine and serotonin concentration were found to be higher (16.27 ± 1.209 and 43.28 ± 1.550 ng/ml) in the EOP-treated group as compared to the pure extract-treated group (10.40 ± 1.185 and 32.79 ± 1.738 ng/ml). Conclusion. Improvement of aqueous solubility, permeability, dissolution, bioavailability, and narrower particle size distribution could facilitate enhancement in the nootropic potential of EOE phytosomal formulation.
- 4 April 2024
- Published by Wiley in Journal of Chemistry
- Vol. 2024, 1-19
Open AccessNovel Phytosomal Formulation of Emblica officinalis Extracts with Its In Vivo Nootropic Potential in Rats: Optimization and Development by Box-Behnken Design
Purpose. The present study aimed to improve the aqueous solubility, permeability, bioavailability, and nootropic potential of standardized Emblica officinalis extract (EOE) by developing a novel phytosomal formulation. Method. Emblica officinalis extract-loaded phytosomes (EOPs) were prepared using solvent evaporation. The EOP was prepared at different molar ratios of extract and phospholipid. Herein, the effects of phospholipid extract ratio (A), temperature (B), and reaction time (C) were systematically investigated on entrapment efficiency using Box-Behnken design. In vitro and in vivo characterizations of the optimized formulation were performed. Results. Optimized EOP formulation (89.90 ± 0.24 μg/ml) exhibited improved aqueous solubility than plain EOE (11.85 ± 0.25 μg/ml). The optimized formulation’s particle size and Zeta potential were 198.4 ± 0.20 nm and −39.0 ± 0.40 mv. DSC and XRD studies confirmed the partial amorphization of EOE in phytosomes. Optimized formulation exhibited 69.82 ± 0.17% of EOE release at 12 h and followed zero-order release kinetics. Moreover, the phytosomal formulation of EOE exhibited its rationality with an improvement of bioavailability by 2.7 folds compared with pure EOE. Compared to EOE, EOP showed significantly ( lower escape and transfer latencies on both days in MWMT and EPMT, indicating more effective memory-enhancing activity. Furthermore, EOP-treated rats exhibited improved acetylcholine (Ach) levels than EOE. Brain tissue concentrations measured following EOP oral administration (1.06 ± 0.04 μg/ml) were substantially greater ( ) than those following EOE (0.32 ± 0.07 μg/ml). The brain dopamine and serotonin concentration were found to be higher (16.27 ± 1.209 and 43.28 ± 1.550 ng/ml) in the EOP-treated group as compared to the pure extract-treated group (10.40 ± 1.185 and 32.79 ± 1.738 ng/ml). Conclusion. Improvement of aqueous solubility, permeability, dissolution, bioavailability, and narrower particle size distribution could facilitate enhancement in the nootropic potential of EOE phytosomal formulation.
- 23 August 2023
- Published by Springer Nature in Chemistry Africa
- Vol. 7 (2) , 1151-1164
Identification of Potential Hits against Fungal Lysine Deacetylase Rpd3 via Molecular Docking, Molecular Dynamics Simulation, DFT, In-Silico ADMET and Drug-Likeness Assessment
- 23 August 2023
- Published by Springer Nature in Chemistry Africa
- Vol. 7 (2) , 1151-1164
Identification of Potential Hits against Fungal Lysine Deacetylase Rpd3 via Molecular Docking, Molecular Dynamics Simulation, DFT, In-Silico ADMET and Drug-Likeness Assessment
- 20 June 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (10) , 5178-5196
Identification of potential biogenic chalcones against antibiotic resistant efflux pump (AcrB) via computational study
The cases of bacterial multidrug resistance are increasing every year and becoming a serious concern for human health. Multidrug efflux pumps are key players in the formation of antibiotic resistance, which transfer out a broad spectrum of drugs from the cell and convey resistance to the host. Efflux pumps have significantly reduced the efficacy of the previously available antibiotic armory, thereby increasing the frequency of therapeutic failures. In gram-negative bacteria, the AcrAB-TolC efflux pump is the principal transporter of the substrate and plays a major role in the formation of antibiotic resistance. In the current work, advanced computer-aided drug discovery approaches were utilized to find hit molecules from the library of biogenic chalcones against the bacterial AcrB efflux pump. The results of the performed computational studies via molecular docking, drug-likeness prediction, pharmacokinetic profiling, pharmacophore mapping, density functional theory, and molecular dynamics simulation study provided ZINC000004695648, ZINC000014762506, ZINC000014762510, ZINC000095099506, and ZINC000085510993 as stable hit molecules against the AcrB efflux pumps. Identified hits could successfully act against AcrB efflux pumps after optimization as lead molecules.Communicated by Ramaswamy H. Sarma.
- 20 June 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (10) , 5178-5196
Identification of potential biogenic chalcones against antibiotic resistant efflux pump (AcrB) via computational study
The cases of bacterial multidrug resistance are increasing every year and becoming a serious concern for human health. Multidrug efflux pumps are key players in the formation of antibiotic resistance, which transfer out a broad spectrum of drugs from the cell and convey resistance to the host. Efflux pumps have significantly reduced the efficacy of the previously available antibiotic armory, thereby increasing the frequency of therapeutic failures. In gram-negative bacteria, the AcrAB-TolC efflux pump is the principal transporter of the substrate and plays a major role in the formation of antibiotic resistance. In the current work, advanced computer-aided drug discovery approaches were utilized to find hit molecules from the library of biogenic chalcones against the bacterial AcrB efflux pump. The results of the performed computational studies via molecular docking, drug-likeness prediction, pharmacokinetic profiling, pharmacophore mapping, density functional theory, and molecular dynamics simulation study provided ZINC000004695648, ZINC000014762506, ZINC000014762510, ZINC000095099506, and ZINC000085510993 as stable hit molecules against the AcrB efflux pumps. Identified hits could successfully act against AcrB efflux pumps after optimization as lead molecules.Communicated by Ramaswamy H. Sarma.
- Open Access
- 1 November 2022
- Published by MDPI AG in Biology and Life Sciences Forum
- Vol. 20 (1) , 14
Enlarging the NSAIDs Family: Molecular Docking of Designed Pyrazole and Oxadiazole Derivatives as Novel Anti-Inflammatory Agents
The development of the NSAID family has represented a excitingapproach in the treatment of inflammatory disorders, such as arthritis, and for the management of acute pain, in relation to the well-known traditional Non-Steroidal Anti-Inflammatory Drugs (t-NSAIDs). Over the years, research has shown that essential mediators such as arachidonic acid metabolites are important in inflammation. The cyclooxygenase (COX) and lipoxygenase (LOX) pathways take primary roles in inflammation and are responsible for many human diseases, such as cancer, arthritis, psoriasis, and neurological disorders. Prompted by the pursuit for new cyclooxygenase-2 (COX-2) inhibitors, we have identified novel classes of pyrazole and oxadiazole derivatives as potentially powerful anti-inflammatory molecules. This virtual screening aims to predict the binding affinity of newly designed pyrazole and oxadiazole derivatives against potential molecular targets related to the inflammatory process through the molecular docking approach. Results showed very good anti-inflammatory activity against cyclooxygenase-2 (COX-2) binding protein 1CX2. Additionally, based on the molecular docking results, it was observed that two molecules have good binding affinity with a targeted protein. The issues gained with these classes of compounds represent, currently, a potent stimulus for the further enlargement of the NSAIDs family.
- 1 November 2022
- Published by MDPI AG in Biology and Life Sciences Forum
- Vol. 20 (1) , 14
Open AccessEnlarging the NSAIDs Family: Molecular Docking of Designed Pyrazole and Oxadiazole Derivatives as Novel Anti-Inflammatory Agents
The development of the NSAID family has represented a excitingapproach in the treatment of inflammatory disorders, such as arthritis, and for the management of acute pain, in relation to the well-known traditional Non-Steroidal Anti-Inflammatory Drugs (t-NSAIDs). Over the years, research has shown that essential mediators such as arachidonic acid metabolites are important in inflammation. The cyclooxygenase (COX) and lipoxygenase (LOX) pathways take primary roles in inflammation and are responsible for many human diseases, such as cancer, arthritis, psoriasis, and neurological disorders. Prompted by the pursuit for new cyclooxygenase-2 (COX-2) inhibitors, we have identified novel classes of pyrazole and oxadiazole derivatives as potentially powerful anti-inflammatory molecules. This virtual screening aims to predict the binding affinity of newly designed pyrazole and oxadiazole derivatives against potential molecular targets related to the inflammatory process through the molecular docking approach. Results showed very good anti-inflammatory activity against cyclooxygenase-2 (COX-2) binding protein 1CX2. Additionally, based on the molecular docking results, it was observed that two molecules have good binding affinity with a targeted protein. The issues gained with these classes of compounds represent, currently, a potent stimulus for the further enlargement of the NSAIDs family.
- 30 November 2021
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 14 (11) , 5683-5690
Differences and Similarities in the Metabolism of Erlotinib across various Species: An Analysis by Liquid Chromatography - Tandem Mass Spectrometry
- 30 November 2021
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 14 (11) , 5683-5690
Differences and Similarities in the Metabolism of Erlotinib across various Species: An Analysis by Liquid Chromatography - Tandem Mass Spectrometry
- 18 January 2021
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 16 (6) , 718-724
Development of 'S', 'N' Heterocycles as Antimycobacterials Targeting Fatty Acid Biosynthesis
Background: Mycobacterium tuberculosis is a causative organism of tuberculosis, which is the most deadly disease after cancer in the current decade. The development of multidrug and broadly drug- resistant strains makes the tuberculosis problem more and more critical. In the last 40 years, only one molecule is added to the treatment regimen. Generally, drug design and development programs are targeted proteins whose function is known to be essential to the bacterial cell. Objectives: Here are the development of 'S', 'N’ heterocycles as antimycobacterials targeting fatty acid biosynthesis are reported. Material and Methods: In the present communication, rational development of anti-mycobacterial agent's targeting fatty acid biosynthesis has been done by integrating the pocket modeling and virtual analysis. Results: The identified potential 33 lead compounds were synthesized, characterized by physicochemical and spectroscopic methods like IR, NMR spectroscopy and further screened for antimycobacterial activity using isoniazid as standard. All the designed compounds have shown profound antimycobacterial activity. Conclusion: In this present communication, we found that 3c, 3f, 3l and 4k molecules had expressive desirable biological activity and specific interactions with fatty acids. Further optimization of these leads is necessary for the development of potential antimycobacterial drug candidates having fewer side effects.
- 18 January 2021
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 16 (6) , 718-724
Development of 'S', 'N' Heterocycles as Antimycobacterials Targeting Fatty Acid Biosynthesis
Background: Mycobacterium tuberculosis is a causative organism of tuberculosis, which is the most deadly disease after cancer in the current decade. The development of multidrug and broadly drug- resistant strains makes the tuberculosis problem more and more critical. In the last 40 years, only one molecule is added to the treatment regimen. Generally, drug design and development programs are targeted proteins whose function is known to be essential to the bacterial cell. Objectives: Here are the development of 'S', 'N’ heterocycles as antimycobacterials targeting fatty acid biosynthesis are reported. Material and Methods: In the present communication, rational development of anti-mycobacterial agent's targeting fatty acid biosynthesis has been done by integrating the pocket modeling and virtual analysis. Results: The identified potential 33 lead compounds were synthesized, characterized by physicochemical and spectroscopic methods like IR, NMR spectroscopy and further screened for antimycobacterial activity using isoniazid as standard. All the designed compounds have shown profound antimycobacterial activity. Conclusion: In this present communication, we found that 3c, 3f, 3l and 4k molecules had expressive desirable biological activity and specific interactions with fatty acids. Further optimization of these leads is necessary for the development of potential antimycobacterial drug candidates having fewer side effects.
- Open Access
- 1 January 2021
- Published by Comprehensive Publications in International Journal of Pharmaceutical Research and Development
- Vol. 3 (2) , 01-03
Comparative evaluation of potato, sweet potato and maize starch as pharmaceutical excipient
The purpose of this study was to isolate starches from Potato, Sweet potato and Maize. The presence of starch in these grains varies and thus their use as pharmaceutical excipients will vary to the degree of their starch functionality. The powders obtained were characterized for their particle size, particle size distribution. The physicochemical characterization such as bulk density, tapped density, Carr’s index and Hausner’s ratio were evaluated. Tablet formulated with potato starch are less friable, harder, showed longer time for disintegration and good drug release profile in comparison to tablets formulated with sweet potato, maize. The results obtained showed that among the three starches in relation to their flowability, potato starch possesses the best flow property. The source of starches therefore affects the properties of pharmaceutical dosage forms. This should be taken into consideration in the choice of excipients in drug formulation and before the substitution of one starch for another in a formulation.
- 1 January 2021
- Published by Comprehensive Publications in International Journal of Pharmaceutical Research and Development
- Vol. 3 (2) , 01-03
Open AccessComparative evaluation of potato, sweet potato and maize starch as pharmaceutical excipient
The purpose of this study was to isolate starches from Potato, Sweet potato and Maize. The presence of starch in these grains varies and thus their use as pharmaceutical excipients will vary to the degree of their starch functionality. The powders obtained were characterized for their particle size, particle size distribution. The physicochemical characterization such as bulk density, tapped density, Carr’s index and Hausner’s ratio were evaluated. Tablet formulated with potato starch are less friable, harder, showed longer time for disintegration and good drug release profile in comparison to tablets formulated with sweet potato, maize. The results obtained showed that among the three starches in relation to their flowability, potato starch possesses the best flow property. The source of starches therefore affects the properties of pharmaceutical dosage forms. This should be taken into consideration in the choice of excipients in drug formulation and before the substitution of one starch for another in a formulation.